Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile.
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile.